News – People with rare autoimmune diseases are at an increased risk of dying during the Covid-19 pandemic

Friday, 04 December 2020

A new study, led by experts from the University of Nottingham, has shown that people with rare autoimmune rheumatic diseases are at a greater risk of dying at a younger age during the Covid-19 pandemic.

The findings of the study, published in the British Society for Rheumatology’s journal, Rheumatology, was the work of a team of doctors and researchers from RECORDER (Registration of Complex Rare Diseases Exemplars in Rheumatology), which is a joint project between the University of Nottingham and the National Disease Registration Service at Public Health England.

Experts looked at the electronic health records of 170,000 people in England with rare autoimmune rheumatic diseases. During March and April 202 (the first two months of the Covid-19 pandemic), the team found that 1,815 (1.1%) of people with these diseases died.

People with rare diseases often have poorer health outcomes generally, so we wanted to find out what impact the Covid-19 pandemic has had. From our study we know that during the early months of the pandemic, people with these diseases were more likely to die than the general population. The next steps in our research are to look at death certificate data and find out why people have died. We’ll be examining whether it’s due to Covid-19 infection or how much is due to the disruption to healthcare services.”

Study co-author, Dr Fiona Pearce from the School of Medicine at the University of Nottingham

The results also showed that:

  • The risk of dying during Covid-19 for people with these conditions increased from age 35
  • Women with rare autoimmune rheumatic diseases had a similar risk of death to men during Covid-19 – whereas usually their risk of death is lower
  • For people of working age with rare autoimmune rheumatic diseases, the risk of dying during Covid-19 was similar to that of someone 20 years older in the general population
Related:  News - Nottingham’s universities and institutions unite to drive local recovery with UK’s first Civic Agreement

Paul Howard, Chief Executive of Lupus UK, said: “This study is an important step in helping us to understand the impact of the Covid-19 pandemic on people with rare autoimmune rheumatic conditions in the UK. The findings demonstrate that, as a group, people with conditions such as lupus have been disproportionately impacted and therefore the provision of additional support is necessary.  

“We hope that the next steps of this research will lead to a clearer understanding about whether Covid-19 or other factors caused the increased mortality, and also whether other health and quality of life measures have been disproportionately affected in these patient groups.” Paul Howard, Chief Executive of LUPUS UK.”

Dr Peter Lanyon, Consultant Rheumatologist at Nottingham University Hospitals NHS Trust, said: “Our study illustrates the unique ability of collaboration with the National Disease Registration Service to generate findings that can improve health in rare diseases. Further work to understand them in greater depth and more support for people with rare autoimmune rheumatic diseases is now needed.”

Dr Sanjeev Patel, President of the British Society for Rheumatology, said: “These results are incredibly important to the rheumatology community. These conditions might be rare, but when we look at them together it’s a significant number of people.

“This is a large study which shows for the first time that a subgroup of patients in our care are at an increased risk of dying during the pandemic and at a much younger age. We don’t yet know the reasons why, but this study brings into sharp focus the need to be more vigilant with these patients and it should help inform future shielding advice.”

The full study can be found here.

Related:  News - Leading scientists call for a National Covid-19 Resilience Programme to keep older people healthy and resilient during lockdown

Story credits

More information is available from Dr Fiona Pearce from the School of Medicine at the University of Nottingham at Fiona.pearce@nottingham.ac.uk

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email  pressoffice@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors:

The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world’s top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia – part of a globally connected network of education, research and industrial engagement. The University’s state-of-the-art facilities and inclusive and disability sport provision is reflected in its status as The Times and Sunday Times Good University Guide 2021 Sports University of the Year. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer and industry partner – locally and globally. Alongside Nottingham Trent University, we lead the Universities for Nottingham initiative, a pioneering collaboration which brings together the combined strength and civic missions of Nottingham’s two world-class universities and is working with local communities and partners to aid recovery and renewal following the COVID-19 pandemic.

More news…


More from: | Category: University News